Body composition adds little to radiotherapy toxicity prediction
Computed tomography-derived muscle measures ranked highly for toxicity and quality of life, but added little predictive value beyond established clinical factors.
Computed tomography-derived muscle measures ranked highly for toxicity and quality of life, but added little predictive value beyond established clinical factors.
Radiotherapy increased tumor uptake of PDL1-targeted radionuclide therapy, while antibody co-dosing reduced splenic trapping and restored antitumor efficacy in mice.
Convergent 60 keV photons matched orthovoltage radiation and showed comparable or greater biological effectiveness than 6 MV photons, depending on cell type.
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
In mice, ultrahigh dose-rate X-rays caused less early testicular damage than conventional irradiation, with protection linked to ferroptosis suppression.
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Radioresistant tumors showed impaired ferroptosis and regulatory T-cell accumulation, while sorafenib enhanced the response to irradiation in mice.
FLASH radiotherapy preserved hepatic structure and metabolic homeostasis while maintaining tumor control in a preclinical breast cancer model.
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose